Poison Pill
A poison pill is a defence a listed company's board adopts against an unwanted takeover: a shareholder rights plan that lets every shareholder except the bidder buy new shares at a deep discount once the bidder's stake crosses a threshold, diluting the bidder so heavily that acquiring control without the board's consent becomes uneconomic.
- Also known as
- Shareholder rights plan, Rights plan, Takeover defence
- Used at
- US listed companies, adopted by the board without a shareholder vote, often within days of an approach
- Trigger
- a shareholder crossing 10–20% of the shares (15% is common)
- Effect
- other shareholders may buy shares at, say, half price; the bidder may not, and is diluted
- Not available everywhere
- the UK Takeover Code and most European regimes forbid boards from frustrating a bid without shareholder approval
- Lifespan
- often 12 months, renewable; courts require boards to show a reasonable threat
How a poison pill works in practice
A bidder that cannot persuade a board to sell can go over its head: buy shares in the market and make a tender offer to the rest. The poison pill makes that route ruinous. The board issues a right to every shareholder that lies dormant until someone crosses the threshold; at that moment every other shareholder can buy new shares at a fraction of the market price, and the bidder's stake — bought at full price — is diluted by half or more. No bidder crosses the line. The real effect is to force the bidder to negotiate with the board, which can redeem the rights for a nominal sum if it agrees a deal.
The pill's defenders say it gives boards time and leverage to get a fair price; its critics say it entrenches management. Delaware courts have upheld it for decades on condition that the board acts in good faith against a real threat, and have struck down pills with thresholds so low or terms so broad that they served the board rather than the shareholders. Outside the United States the device is largely unavailable: a UK board facing a bid may not act to frustrate it without shareholder approval, and defence means arguing the price is too low.
For fintechs the pill matters at one moment — after listing, when the share price has fallen below the value of the business and a larger competitor or a fund sees a bargain. The activist investor building a stake for influence rather than control is the other trigger, and the threshold is set with them in mind.
Example
A listed payments company's shares fall 60% in a year. A larger rival buys 9% in the market and writes to the board proposing an acquisition at a 25% premium. The board adopts a rights plan with a 12% trigger: if any holder crosses it, every other shareholder may buy one new share at 50% of market price for each share held. The rival stops buying at 9% and negotiates; four months later the board agrees a deal at a 48% premium and redeems the rights. Had the rival crossed 12%, its 12% stake would have become roughly 6.5% after the other shareholders exercised.
Common mistakes
- Adopting a pill with a threshold low enough to catch passive investors, which invites a court challenge. - Using it to block a bid the shareholders want, and losing the board at the next election. - Assuming the device exists under UK or European takeover rules — it does not. - Bidders ignoring an existing pill and buying through the threshold. - Boards treating the pill as a strategy: it buys time, and time has to be used.